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Arrays Cast
Toxicology in a
New Light
Out on the San Diego beaches in January
2000, the breezes were warm and soft, but
inside the Hilton Resort, at a special ses-
sion of the American Association for
Cancer Research conference on DNA
repair defects, a storm was boiling. 
Leona Samson, director of the Bio-
chemical and Experimental Toxicology
Research Core at Harvard’s Kresge Center
for Environmental Health and a Harvard
School of Public Health professor of toxi-
cology, had just presented new data show-
ing that the typical response to certain
DNA-damaging agents by yeast cell gene
expression was much more complicated
than ever previously seen, or even suspect-
ed, and that many more genes were
involved than previously imagined. “It
made quite a splash,” she recalls. “I was
surrounded by a sea of people, and I
remember one person saying, ‘Oh my
God, I should probably just give up what
I’m doing.’”
Working at the Kresge Center, one of
the NIEHS’s 21 environmental health sci-
ences centers, and using microarray tech-
nology, which allows scientists to watch an
organism-wide response to DNA damage,
Samson and her labmates found that expo-
sure to alkylating agents, widely used as a
model system for studying cellular respons-
es to DNA damage, evoked at least three-
fold changes in expression in one-third of
the yeast genome, or about 2,000 genes.
The news came as a shock to scientists,
who had believed that the response to alky-
lating agents was limited solely to DNA
repair genes. 
Even Samson herself, who has spent
her entire career studying specific DNA
repair mechanisms, was struck by her own
results. “We were, in a sense, frightened at
how big the response was,” she recalls.
“We said, ‘What are we going to do with
so many genes?’”
Genomics, the study of how cells’
entire genetic complement responds to
environmental and internal stimuli, is
rocking the boat in the field of toxicology.
The impact of new waves of information
has resonated throughout the field, and has
more researchers talking about toxico-
genomics. This approach to studying toxi-
cology focuses on cellular changes in gene
expression and could change the way toxi-
cants are detected and classified. 
Many researchers who would like to
obtain the hardware themselves have been
left out by the high cost of the technology.
While genomic arrays are spreading rela-
tively quickly through the industrial com-
munity, academic toxicologists have been
less able to shoulder the considerable costs
of using microarrays. A single 6,200-gene
chip currently costs about $1,000. 
However, microarrays make it possible
to discover in a matter of days or weeks
what would have once taken years to do.
Cells are grown, then split into control and
treated groups. Isolated pieces of RNA are
labeled with a fluorescent dye and then
allowed to hybridize to chips, each of
which is studded with up to 40 oligonu-
cleotides complementary to each of the
6,200 specific yeast genes and open read-
ing frames (areas that are likely to be pro-
tein-coding regions of the genome). A
scanning confocal microscope can measure
changes in fluorescence as low as twofold. 
Heading in a New Direction
In 1997, Samson and then-postdoctoral stu-
dent Scott Jelinsky, now a staff scientist at
Genetics Institute in Boston, Massachusetts,
were discussing which line of investigation
he should pursue when they heard about a
user program offered by Affymetrix, a Santa
Clara, California, company that makes the
inches-square chips on which genomic stud-
ies are performed. Another Harvard labora-
tory, headed by George Church, already
had much of the equipment needed to use
the chips, so Jelinsky took two trips to
California, where he learned to set up exper-
iments and collect expression data.
Not long afterward, the Samson lab
began its first genomic studies of the
effects of methyl methanesulfonate on
yeast, later published in the February 1999
issue of Proceedings of the National Acad-
emy of Sciences. This preliminary snapshot
showed that expression of 325 genes was
up-regulated after exposure to the alkylat-
ing agent, while 76 genes were down-regu-
lated. This meant that far more genes were
somehow involved in a response to DNA
damage than scientists had previously
believed.
Samson had spent most of her career
focusing her attention on the response to
alkylation of DNA repair genes such as
MAG1. MAG1’s protein product initiates
the removal and replacement of damaged
DNA base pairs by recognizing and excis-
ing damaged bases. MAG1 is found in a
wide variety of species, including various
plants, insects, fish, rodents, and humans. 
That MAG1 seemed lost in such a
cacophony of gene expression suggested a
much broader, more complicated response
to cellular damage than Samson had ever
imagined. “But when we sat down to write
the paper,” she recalls, “it dawned on me
that we’re flooding cells with a highly reac-
tive chemical; of course it’s going to
change lots of things. These organisms are
exquisitely tuned to sense what’s going on
in their environment. If you have a chemi-
cal that reacts with virtually every class of
molecule in the cell, it’s going to respond
when things are changed. So I’m no longer
surprised by the breadth of response.” 
Still, the task of interpreting the results
seemed daunting. Hoping to shed some
light on the rhyme and reason of all this
activity, Samson and her colleagues decided
to broaden the study to look at cells at vari-
ous time points after exposure to a variety
of alkylating agents, including methyl
methanesulfonate. All in all, they per-
formed 26 transcriptional profiles, which,
as Samson notes, would have taken years
with the standard Northern blot techniques
they had been using only months earlier to
do similar studies. When 2,000 yeast genes
appeared to have been affected by the
agents, Samson knew that she had to find
some way to fathom the results. Her answer
was to look back at MAG1.
“We tried to get our arms around it by
asking a question from our own expertise,”
Samson says. “‘[What other gene] behaves
the same as MAG1?’ It was an obvious
question.”
That question turned out to have
provocative answers. Thirty-three protein
degradation genes, or proteasomes, along
with four additional DNA repair genes
A 20 VOLUME 109 | NUMBER 1 | January 2001 • Environmental Health Perspectives
NIEHS Newsturned out to be coregulated with MAG1,
meaning that the protein expression of the
genes rises and fall together because they
are regulated by the same genetic elements,
or factors. It had never before occurred to
Samson that protein degradation would
walk hand-in-hand with DNA repair, but
it was totally logical, she says, that faulty
proteins would have to be removed before
fresh ones could be expressed and installed. 
“We had been doing very traditional
reductionist biology and concentrating on
repair pathways,” she says. “But by looking
globally with genome arrays, we were
forced to open our eyes to what was there
and ask questions about other genes.”
The coregulation of DNA repair and
protein degradation genes became even
clearer when Jelinsky found that a genetic
element regulating MAG1 that they had
identified eight years ago is identical to a
regulator of the proteasomes. By reviewing
and analyzing the overall expression
response to toxicants, he and Samson had
unearthed new dimensions of the damage
response and found the responsible DNA
machinery. 
A More Creative Approach
Formerly unimpressed with the vast
amounts of data churned forth by genomic
studies, researchers are now thinking more
creatively about the analytic approaches.
“We need to think about patterns and
shapes in the data,” says Samson. “I think
in the end it will come back to individual
genes. But first we can look at how a stimu-
lus affects an organism’s entire biology, and
then we can begin dissecting the response.”
Genomic arrays allow toxicologists to
look at cellular behavior in a completely
new light. In a sense, recording individual
gene responses to powerful insults such as
alkylating agents was akin to studying the
effects of poverty by monitoring a person’s
bank account—the complete picture is
much larger than what is actually being
measured. But genomic arrays simultane-
ously report indicators of multiple dimen-
sions of the cellular response to stimuli.
Now, in addition to gaining insight into
basic cellular mechanisms of repair,
researchers looking at a variety of indica-
tors and responses of toxicity may gain
some predictive power regarding individual
compounds—and individual humans. 
Both academic and private laboratories
have already begun work on finding genes
that induce protection or sensitivity to tox-
icants in individual cells and people.
Spencer Farr, founder and CEO of Phase-
1 Molecular Toxicology, based in Santa
Fe, New Mexico, says that genomic analy-
sis of individual response to substances will
challenge scientific assumptions about the
nature of toxicity. 
“Our experiments are based on the idea
that there’s an ‘average person’ that typifies
our response to toxicants,” says Farr. “The
reality is that, no matter what toxicant or
compound you’re looking at, there are
always going to be subpopulations that
react differently from the norm.”
Farr believes that toxicogenomics could
revolutionize the study and implementa-
tion of drugs that cause dangerous side
effects in defined patient subgroups. The
psychoactive drug clozapine, for example,
causes dangerous blood-clotting disorders
in about 5% of patients. Toxicogenomic
studies of vulnerable patients could lead to
the identification of vulnerability genes or
gene patterns that could be cheaply detect-
ed with mini-arrays. Farr’s company is
concentrating on gene expression in the
liver, kidneys, and other organs that are
often targeted by drugs. 
Farr also believes toxicogenomics will
become increasingly important in preclini-
cal drug studies. “Rats predict carcinogenic-
ity in mice with only about 50% accuracy,”
he points out. “How predictive do you
think either of them are in human reactions
to drugs? Using gene expression and analy-
sis, I believe that we can do a better job of
predicting who will suffer adverse outcomes
from all kinds of substances.” 
A number of laboratories are also gear-
ing up to begin studying how to predict
the toxicity of a given substance by com-
paring patterns of evoked gene expression
among new and known compounds. This
could be particularly useful in gauging the
potential impact of long-term exposures,
or the effects of certain compounds on
fetal development. 
Investing in the Future
Samson’s lab is now looking for ways to
lower the cost of doing toxicogenomics by
making their own chips. Led by Thomas
Begley, a postdoctoral fellow in her lab,
Samson’s staff is currently amplifying each
of yeast’s 6,200 genes and cross-linking
them to lysine-coated slides. For an initial
investment of about $100,000, Begley says,
the lab will make chips for several dollars
apiece. Soon, they will be using them to
study gene expression in Escherichia coli and
other model systems, including higher
organisms such as knockout mice. 
At this point, the greatest obstacle to
the spread of toxicogenomics may remain
in interpreting the multitudes of data that
pour out of each slide. At this point, it’s
difficult to say what the crests and valleys
of gene expression mean—whether an
increase in the expression of a particular
gene indicates involvement in protection
or vulnerability to a toxicant. 
“There’s a waiting aspect to this,” says
Harvard professor of toxicology Armen
Tashjian, Samson’s predecessor as core
director at the Kresge Center. “People are
still looking for validation, and that’s going
to come with time and more experiments.”
For her part, Samson feels that the time
has come for more scientists to look at
genomics as a guide to their research, rather
than as a threatening alternative to current
approaches of studying single or small num-
bers of genes. “These kinds of profiles have
to be made available for everyone to look
at,” she says. “The data should be there for
everyone. We’re looking at the data from
one simple point of view, but I think they
need to be examined from each person’s
point of view, which relates to their own
area of expertise.” –John F. Lauerman
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Stroke of Gene-ius
NIEHS scientists are working with the
Human Genome Project to make envi-
ronmental medicine uniquely individual.
On 7 December 2000, the NIEHS offi-
cially opened the National Center for
Toxicogenomics (NCT) to begin studying
how thousands of genes interact and
respond to environmental exposures dur-
ing different stages of health and disease.
Some of the diseases associated with envi-
ronmental factors that toxicogenomics
may help to elucidate include cancer, pul-
monary disease, neurodegenerative disor-
ders, developmental disorders, birth
defects, reproductive dysfunction, and
autoimmune disease. Toxicogenomics is a
relatively new field that uses microarray
technology and incorporates information
from the Human Genome Project to
develop highly individual toxicologic
assays. Thus, says Ben Van Houten, the
coordinator for the new center, the field
offers the “interesting ability to personal-
ize medicine.” 
Toxicogenomics tracks simultaneously
the response of thousands of genes to
environmental stimuli using glass slides of
DNA combined with computational data
analysis of the genes. The NIEHS has
developed an innovative  microarray tech-
nology called the ToxChip, and is build-
ing a library of ToxChip patterns that will
eventually represent all known toxicants.
Such tools should give environmental
health researchers the ability to identify
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Environmental
Genome Project:
A Positive Sequence
of Events
Why does one person develop disease fol-
lowing exposure to a certain environmen-
tal agent but another person doesn’t? That
question lies at the heart of the NIEHS’s
Environmental Genome Project (EGP),
begun in late 1997. To find an answer, the
EGP is studying variations of certain genes
and their interactions with the environ-
ment. Scientists believe that if they can
understand what comprises genetic sus-
ceptibility to environmental agents, they
will be able to determine or predict what
the true risks of exposures are, and suscep-
tible individuals can be better protected.
The scientific community has identi-
fied some 500 genes as being responsive to
environmental factors such as diet and
exposure to particular exogenous agents.
The EGP is especially interested in the
genes in two specific categories, DNA
repair and cell cycle control, although
these are not the only types of genes being
studied. Currently, the EGP sponsors
genome centers at the University of
Washington and the University of Utah
where much of the resequencing research
is being conducted. 
The first step in understanding the
provenance of what have been called
“environmentally related diseases” is to
resequence environmentally responsive
genes to determine their possible allelic
variations (single nucleotide polymor-
phisms, or SNPs). SNP variations play a
key role in explaining why people react in
different ways to different exposures.
Perhaps the most exciting product of
the EGP to date is a central database of
gene SNPs—the only one of its kind—
which presents the information gathered
through the EGP on an easy-to-use Web
site. Housed at the Utah Genome Center,
the database is accessible through the
GeneSNPs link on the EGP home page at
http://www.niehs.nih.gov/envgenom/.
The database is constantly being updated
and currently contains information on
485 different genes. Entries for each SNP
include its length, genomic position, and
frequency, as well as a model of the gene. people who are at particular risk for being
harmed by specific toxicants by enabling
them to study how genes respond to par-
ticular chemicals. This may allow scien-
tists to predict who might be susceptible
to developing a particular disease and
what the potential adverse responses
might be. 
The research produced by toxicoge-
nomic studies promises to contribute to
advancing intervention and prevention
approaches to environmental diseases.
The NCT will work closely with the
Environmental Genome Project to refine
gene expression study techniques to help
pinpoint variances in genetic susceptibili-
ty among people. NIEHS researchers are
in the process of resequencing DNA
repair enzyme and cell cycle control
genes. Center projects will further work
toward expanding the knowledge base on
proteomics, or the micro-level study of
proteins. 
The NCT’s database will eventually
include the 20 years of toxicologic data
contained in the National Toxicology
Program archives. Van Houten says that
although not all the data have been
entered into a computer yet, the ultimate
goal is to link this information to the
NCT’s database.
Toxicogenomics will also help guide
federal agencies and legislators to develop
guidelines and laws that regulate the con-
centrations of various chemicals in the
environment. Guidelines based on firm
scientific data will provide a strong basis
for health-related policy and regulation.
–Lindsey A. Greene
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The next step in understanding the
relationship between genes, environment,
and disease is functional analysis—under-
standing the biologic signficance of gene
variations, and how variations cause their
respective effects. Under the auspices of the
EGP, grants for up to five Comparative
Mouse Genomics Centers across the
United States and Europe will be made by
April 2001. The centers will develop
mouse models that mimic human gene
variations in order to examine the func-
tional implications of these variations.
In addition to resequencing and func-
tional analysis studies, the EGP funds pop-
ulation-based studies, which examine how
different SNPs are distributed through vari-
ous U.S. subpopulations and how they
affect their carriers in terms of increased
disease susceptibility or resistance. The
NIEHS Division of Extramural Research
and Training is in the process of developing
programs to distribute planning grants for
molecular epidemiologists. Once SNPs are
determined, the EGP will need people who
can assess the frequency of SNP expression
in the population. Molecular epidemiolo-
gists will be trained to effectively translate
the data currently being generated by the
EGP into population-based research.
Other components of the EGP include
biostatistics/bioinformatics projects to
develop statistical and computer models
for analyzing gene–environment interac-
tions, and to develop means for analyzing
data on macromolecular cellular compo-
nents such as DNA and proteins. In addi-
tion, technology development projects will
create better, faster ways to conduct EGP
studies. Finally, ethical, legal, and social
implications projects look at developing
policies to address the complex issues
raised by the ability to delve deeply into an
individual’s DNA. 
The NIEHS is also involved in an
interagency agreement with Lawrence
Livermore National Laboratory to rese-
quence a subset of 40–50 genes to deter-
mine the major background SNPs in the
U.S. population. To date, resequencing has
been completed for 15 genes among 90
disease-free people representing the racial
distribution of the United States, with 18
more in progress. The project will next
search the DNA of people with particular
disease for SNPs that may be implicated in
disease causation. –Susan M. Booker